Literature DB >> 9226836

Assessment of the immunogenic potential of Rhodococcus equi virulence associated protein (VapA) in mice.

J F Prescott1, M C Patterson, V M Nicholson, B Morein, J A Yager.   

Abstract

The development of immunity to Rhodococcus equi, particularly to a virulence-associated protein (VapA) based antigen preparation, was examined in CD1 and BALB/c mice after intraperitoneal vaccination. Immunization with VapA based antigen without adjuvant markedly enhanced organ clearance in CD1 mice but not in BALB/c mice. Delayed type hypersensitivity response and antibody titres in VapA based antigen immunized BALB/c mice were less than in CD1 mice. By contrast also to CD1 mice, sera from immunized BALB/c mice did not react as strongly with VapA in western blots. Use of adjuvants (aluminium hydroxide, iscoms) interfered markedly with the immunogenic properties of the VapA based antigen, in the case of aluminium hydroxide by apparently driving a Th2 type of response. Unexpectedly, iscom adjuvants also impaired immunity and, despite the highest DTH response, produced a low IgG2a response, suggesting that iscomization of the antigen produced a low interferon gamma and high interleukin 2 response. Passive immunization of BALB/c mice with serum from mice immunized with live virulent strain 103+ resulted in only temporary and slight enhancement of organ clearance, supporting the central importance of cellular immunity to R. equi. Immunization with live virulence plasmid- and VapA-positive R. equi strain 103 resulted in marked liver clearance, in marked DTH response and high antibody titres. By contrast, immunization with live virulence plasmid- and VapA-negative strain 103 resulted in slight but variable enhancement of clearance, but insignificant DTH and antibody. The virulence plasmid, and by implication VapA, was thus shown to be critical in determining a highly effective protection to live organisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226836     DOI: 10.1016/s0378-1135(97)00090-4

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

1.  Cytokine induction in murine macrophages infected with virulent and avirulent Rhodococcus equi.

Authors:  S Giguère; J F Prescott
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

2.  Mutation and virulence assessment of chromosomal genes of Rhodococcus equi 103.

Authors:  Yanlong Pei; Valeria Parreira; Vivian M Nicholson; John F Prescott
Journal:  Can J Vet Res       Date:  2007-01       Impact factor: 1.310

3.  Role of the 85-kilobase plasmid and plasmid-encoded virulence-associated protein A in intracellular survival and virulence of Rhodococcus equi.

Authors:  S Giguère; M K Hondalus; J A Yager; P Darrah; D M Mosser; J F Prescott
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

4.  B-Cell epitope mapping of the VapA protein of Rhodococcus equi: implications for early detection of R. equi disease in foals.

Authors:  T Vanniasinkam; M D Barton; M W Heuzenroeder
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

5.  Vaccination of Mice with Virulence-Associated Protein G (VapG) Antigen Confers Partial Protection against Rhodococcus equi Infection through Induced Humoral Immunity.

Authors:  Marcel M Trevisani; Ebert S Hanna; Aline F Oliveira; Silvia A Cardoso; Maria C Roque-Barreira; Sandro G Soares
Journal:  Front Microbiol       Date:  2017-05-11       Impact factor: 5.640

6.  Vaccination of mice with salmonella expressing VapA: mucosal and systemic Th1 responses provide protection against Rhodococcus equi infection.

Authors:  Aline F Oliveira; Luciana P Ruas; Silvia A Cardoso; Sandro G Soares; Maria-Cristina Roque-Barreira
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

7.  An Adenoviral Vector Based Vaccine for Rhodococcus equi.

Authors:  Carla Giles; Olasumbo Ndi; Mary D Barton; Thiru Vanniasinkam
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.